Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Travere Therapeutics Inc (NASDAQ: TVTX) closed the day trading at $5.85 up 2.27% from the previous closing price of $5.72. In other words, the price has increased by $2.27 from its previous closing price. On the day, 1.1 million shares were traded. TVTX stock price reached its highest trading level at $5.935 during the session, while it also had its lowest trading level at $5.705.
Ratios:
For a better understanding of TVTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.47. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.99.
On December 05, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $10.
On November 20, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $7.Citigroup initiated its Neutral rating on November 20, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 11 ’24 when Cline Christopher R. sold 54 shares for $6.74 per share. The transaction valued at 364 led to the insider holds 70,849 shares of the business.
Dube Eric M sold 19,122 shares of TVTX for $166,435 on Feb 01 ’24. The CHIEF EXECUTIVE OFFICER now owns 350,600 shares after completing the transaction at $8.70 per share. On Feb 01 ’24, another insider, REED ELIZABETH E, who serves as the SVP, GC & CORPORATE SECRETARY of the company, sold 4,764 shares for $8.71 each. As a result, the insider received 41,495 and left with 76,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 445236480 and an Enterprise Value of 283109152. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.24 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 1.949 whereas that against EBITDA is -0.837.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.68, which has changed by -0.72129583 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $22.75, while it has fallen to a 52-week low of $5.25. The 50-Day Moving Average of the stock is -22.89%, while the 200-Day Moving Average is calculated to be -39.39%.
Shares Statistics:
Over the past 3-months, TVTX traded about 1.16M shares per day on average, while over the past 10 days, TVTX traded about 1439320 shares per day. A total of 75.37M shares are outstanding, with a floating share count of 75.03M. Insiders hold about 1.41% of the company’s shares, while institutions hold 113.82% stake in the company. Shares short for TVTX as of 1711584000 were 10601943 with a Short Ratio of 9.10, compared to 1709164800 on 10260892. Therefore, it implies a Short% of Shares Outstanding of 10601943 and a Short% of Float of 15.67.
Earnings Estimates
At present, 11 analysts are actively evaluating the performance of Travere Therapeutics Inc (TVTX) in the stock market.On average, analysts expect EPS of $-0.97 for the current quarter, with a high estimate of $-0.55 and a low estimate of $-1.27, while EPS last year was $-1.27. The consensus estimate for the next quarter is $-0.82, with high estimates of $-0.63 and low estimates of $-1.08.
Analysts are recommending an EPS of between $-2.43 and $-4.1 for the fiscal current year, implying an average EPS of $-3.18. EPS for the following year is $-1.75, with 11 analysts recommending between $0.16 and $-2.46.
Revenue Estimates
13 analysts predict $44.37M in revenue for the current quarter. It ranges from a high estimate of $60.85M to a low estimate of $38M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $56.99M, an estimated decrease of -22.10% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $51.75M, a decrease of -13.30% over than the figure of $-22.10% in the same quarter last year. There is a high estimate of $66M for the next quarter, whereas the lowest estimate is $42M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $267M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $216.11M. In the same quarter a year ago, actual revenue was $145.24M, up 48.80% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $309.08M in the next fiscal year. The high estimate is $513.31M and the low estimate is $218M. The average revenue growth estimate for next year is up 43.00% from the average revenue estimate for this year.
